HRT Financial LP Invests $816,000 in Option Care Health, Inc. (NASDAQ:OPCH)

Posted by Defense World Staff on Jun 2nd, 2023

HRT Financial LP bought a new position in shares of Option Care Health, Inc. (NASDAQ:OPCH – Get Rating) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 27,119 shares of the company’s stock, valued at approximately $816,000.

Several other large investors have also made changes to their positions in the business. BlackRock Inc. raised its stake in shares of Option Care Health by 20.7% during the 3rd quarter. BlackRock Inc. now owns 19,187,400 shares of the company’s stock worth $603,829,000 after buying an additional 3,290,272 shares during the period. Vanguard Group Inc. increased its position in shares of Option Care Health by 8.1% during the third quarter. Vanguard Group Inc. now owns 15,269,619 shares of the company’s stock worth $480,534,000 after purchasing an additional 1,147,767 shares in the last quarter. Marshall Wace LLP grew its holdings in Option Care Health by 27.1% in the 3rd quarter. Marshall Wace LLP now owns 5,000,053 shares of the company’s stock valued at $157,355,000 after buying an additional 1,066,480 shares in the last quarter. State Street Corp grew its holdings in Option Care Health by 8.2% in the 3rd quarter. State Street Corp now owns 4,841,602 shares of the company’s stock valued at $152,365,000 after buying an additional 365,213 shares in the last quarter. Finally, Bellevue Group AG grew its holdings in Option Care Health by 10.6% in the 1st quarter. Bellevue Group AG now owns 3,232,787 shares of the company’s stock valued at $92,328,000 after buying an additional 308,744 shares in the last quarter. 97.63% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Michael Bavaro sold 6,148 shares of the stock in a transaction dated Friday, March 10th. The stock was sold at an average price of $31.45, for a total value of $193,354.60. Following the completion of the sale, the insider now owns 21,549 shares in the company, valued at $677,716.05. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.38% of the company’s stock.

Option Care Health Stock Up 0.7 %

OPCH opened at $27.73 on Friday. The business’s fifty day moving average is $30.07 and its two-hundred day moving average is $29.86. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.26 and a current ratio of 1.66. The company has a market cap of $4.98 billion, a price-to-earnings ratio of 31.87, a PEG ratio of 1.94 and a beta of 1.15. Option Care Health, Inc. has a one year low of $24.23 and a one year high of $35.87.

Option Care Health (NASDAQ:OPCH – Get Rating) last released its earnings results on Wednesday, May 3rd. The company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.17 by $0.04. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $996.05 million. Option Care Health had a return on equity of 11.90% and a net margin of 3.94%. Analysts anticipate that Option Care Health, Inc. will post 0.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on OPCH shares. Barrington Research decreased their target price on Option Care Health from $38.00 to $34.00 in a research note on Friday, May 5th. Jefferies Financial Group started coverage on Option Care Health in a research note on Monday, February 27th. They set a “buy” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on Option Care Health from $39.00 to $32.50 in a research note on Friday, May 5th.

Option Care Health Profile

(Get Rating)

Option Care Health, Inc engages in the provision of home and alternate site infusion services. The firm provides infusion therapy and other ancillary healthcare services through a national network of full-service pharmacies. The company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings.